To include your compound in the COVID-19 Resource Center, submit it here.

Lovenox enoxaparin: Phase III data

In the open-label, international Phase III ATOLL trial in 910 patients, 0.5 mg/kg IV Lovenox administered prior

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE